Avaliação da resposta à eritropoetina no tratamento de pacientes portadores de síndrome mielodisplásica

Abstract

This study aimed to evaluate the response to erythropoietin in the treatment of patients with Myelodysplastic Syndromes (MDS). During the analysis of variables that could be involved in this response, it was possible to establish a strong association (Phi and Cramer's V of 0.67) (p = 0.000) among patients who responded to treatment with erythropoietin and were not transfusion dependents and between those who did not respond to treatment and were transfusion dependents. The pretreatment hemoglobin showed a median of 10.3g/dl for patients who responded to erythropoietin and 7.2g/dl for patients who did not respond to erythropoietin (p = 0.001). Ferritin among the group with EPO response had a median of 297 ng/ml compared to a median of 653 ng/ml for the group that did not respond to treatment (p = 0.033). Patients who responded to EPO presented media survival of 2376 days (95% CI 2031-2722) and non-responders, 1470 (95% CI 1184-1757) (p = 0.035), corroborating that response to treatment is able to change survival of patients with low risk MDS. Thus, we conclude that the concentration levels of low hemoglobin, high ferritin levels and transfusion dependence has a negative impact on the response to erythropoietin.